advice

Alto Neuroscience Announces Additional Funding of $60 Million

– New investor Alpha Wave Ventures has invested $25 million as part of Series B, extending the operating runway until 2025. – – Alto entered into a $35 million credit facility with K2 HealthVentures – – The company is now funded through four placebo-controlled phase 2 studies with four different product candidates for three different …

Alto Neuroscience Announces Additional Funding of $60 Million Read More »

ObsEva announces the rejection of moratorium procedures

Ad hoc publication based on Art. 53 LR of the Swiss Stock Exchange SIX GENEVA, Switzerland– December 19in 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company that develops and commercializes new therapies for women’s health, announced today that the competent court in Geneva, Switzerland approved the Company’s request to lift the moratorium, …

ObsEva announces the rejection of moratorium procedures Read More »

Vertex and SpliSense address CF with novel inhaled mRNA approaches

Courtesy of Getty Images Oh, what mRNA can do – is a common refrain this week. On Tuesday, Moderna and Merck announced that their investigational mRNA cancer vaccine improved outcomes in relapse-free survival in advanced melanoma. More quietly on Monday, Vertex announced approval of a new drug application for VX-522, an mRNA therapy designed to …

Vertex and SpliSense address CF with novel inhaled mRNA approaches Read More »

Vincerx Pharma Presents Preclinical Data on VIP943 in Models of Acute Myeloid Leukemia at the 2022 American Society of Hematology 64th Annual Meeting.

Vincerx’s proprietary carrier and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with significantly improved safety in non-human primates (NHPs) compared to Mylotarg™ (gemtuzumab ozogamicin). VIP943 demonstrated monotherapy activity in ex vivo AML models and in vivo activity with significant tumor regression in combination with venetoclax and azacitidine …

Vincerx Pharma Presents Preclinical Data on VIP943 in Models of Acute Myeloid Leukemia at the 2022 American Society of Hematology 64th Annual Meeting. Read More »

Kymera Therapeutics Presents Preclinical Data Showing Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in AML xenograft models KT-253 showed combinatorial benefit with the BCL-2 inhibitor venetoclax in a model of venetoclax-resistant AML KT-253 is also active in other hematologic malignancies including DLBCL WATERTOWN, Massachusetts, Dec. 11, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, …

Kymera Therapeutics Presents Preclinical Data Showing Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting Read More »

Coagulant Therapeutics presents data on activated protein C (APC) exosite-specific nanobody library at the American Society of Hematology (ASH) 2022 Annual Meeting.

The oral presentation describes the unique library of APC nanobodies and its potential as a source for novel treatments of diseases including trauma, hemophilia, ischemia and sepsis. SAN FRANCISCO, Dec. 11, 2022 /PRNewswire/ — Coagulant Therapeutics Corporation, a privately held company focused on the design, development and commercialization of therapeutics targeting the coagulation cascade and …

Coagulant Therapeutics presents data on activated protein C (APC) exosite-specific nanobody library at the American Society of Hematology (ASH) 2022 Annual Meeting. Read More »